Welcome
Support Centre
22 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised controlled trial of nasal constant positive airway pressure (NCPAP) as primary therapy for respiratory distress syndrome (RDS) in very pre-term infants.
ISRCTN ISRCTN68552342
ClinicalTrials.gov identifier
Public title A randomised controlled trial of nasal constant positive airway pressure (NCPAP) as primary therapy for respiratory distress syndrome (RDS) in very pre-term infants.
Scientific title
Acronym N/A
Serial number at source N0128138699
Study hypothesis Early intubation and surfactant therapy followed by extubation to NCPAP in preterm infants of less than 29 weeks gestation with RDS when compared to continued intubation and intermittent positive pressure ventilation (IPPV) will result in a 50% reduction in chronic lung disease (CLD) (O2 dependency at 36 weeks post menstrual age).
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Neonatal Diseases: Respiratory
Participants - inclusion criteria 200 infants
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 07/10/2003
Anticipated end date 01/03/2009
Status of trial Completed
Patient information material
Target number of participants 200 infants
Interventions Early intubation and surfactant therapy followed by extubation to NCPAP compared with continued intubation and intermittent positive pressure ventilation (IPPV)
Primary outcome measure(s) Proportion of infants receiving added oxygen and/or respiratory support at 36 weeks post menstrual age.
Secondary outcome measure(s) 1. Days of respiratory support
2. Days of added oxygen
3. Death
4. Pneumothorax rate
5. Sepsis rate (positive blood culture)
6. Trauma rates (nasal septal injury, tracheal stenosis)
7. Change in weight and head circumference centiles between birth and discharge (Z scores).
Sources of funding Liverpool Women's Hospital NHS Trust (UK)
Trial website
Publications
Contact name Prof  Richard  Cooke
  Address Liverpool Women's Hospital
Crown Street

  City/town Liverpool
  Zip/Postcode L8 7SS
  Country United Kingdom
  Tel +44 (0)151 708 9988
  Email
Sponsor Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
  Address The Department of Health,
Richmond House,
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2004
Last edited 18/04/2008
Date ISRCTN assigned 30/09/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central